TAF alone vs TAF with ETV for hepatitis B liver cancer
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests if taking tenofovir alafenamide (TAF) alone works as well as combining it with entecavir (ETV) to improve outcomes for people with hepatitis B and liver cancer who are receiving immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have had hepatitis B for at least 6 months.
- Your hepatitis B virus level (HBV DNA) must be 2,000 IU/mL or higher, checked within the last 2 weeks.
- You have liver cancer that cannot be removed by surgery or has spread to other parts, and you are scheduled to start immunotherapy.
- Your liver function must be good enough (Child-Pugh A or B) and you should be able to care for yourself (ECOG 0 or 1).
- You cannot have hepatitis C or HIV, or have had an organ transplant.
- You should not have heart or kidney failure, or an active autoimmune disease that would prevent immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This study tracks chronic hepatitis B patients who have a family history of liver cancer to understand their risk. It tests how well current antiviral treatments work in this group.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
This trial tests a new two-drug combination for people with chronic hepatitis B who have had their liver cancer completely removed. The goal is to see if the combination can better control the hepatitis B virus.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.